Molecular pathways and potential therapeutic targets in glioblastoma multiforme

Zabi Wardak, Kevin S. Choe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poor. Utilizing powerful large-scale molecular techniques, several key pathways implicated in gliomagenesis have recently been identified and confirmed. These represent potential therapeutic targets, and by developing novel methods to specifically manipulate these pathways, we may achieve a meaningful and substantial improvement in the way we treat GBM. Here, we present and discuss the current status of research into the molecular pathways and potential therapeutic targets in GBM.

Original languageEnglish (US)
Pages (from-to)1307-1318
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume13
Issue number11
DOIs
StatePublished - 2013

Fingerprint

Glioblastoma
temozolomide
Chemoradiotherapy
Therapeutics
Brain
Research
Neoplasms

Keywords

  • GBM
  • glioblastoma
  • glioma
  • glioma stem cells
  • molecular target
  • radiation
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Molecular pathways and potential therapeutic targets in glioblastoma multiforme. / Wardak, Zabi; Choe, Kevin S.

In: Expert Review of Anticancer Therapy, Vol. 13, No. 11, 2013, p. 1307-1318.

Research output: Contribution to journalArticle

@article{e5ae98eb18524d0a8b0ae7b311fffc3f,
title = "Molecular pathways and potential therapeutic targets in glioblastoma multiforme",
abstract = "Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poor. Utilizing powerful large-scale molecular techniques, several key pathways implicated in gliomagenesis have recently been identified and confirmed. These represent potential therapeutic targets, and by developing novel methods to specifically manipulate these pathways, we may achieve a meaningful and substantial improvement in the way we treat GBM. Here, we present and discuss the current status of research into the molecular pathways and potential therapeutic targets in GBM.",
keywords = "GBM, glioblastoma, glioma, glioma stem cells, molecular target, radiation, targeted therapy",
author = "Zabi Wardak and Choe, {Kevin S.}",
year = "2013",
doi = "10.1586/14737140.2013.852472",
language = "English (US)",
volume = "13",
pages = "1307--1318",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Molecular pathways and potential therapeutic targets in glioblastoma multiforme

AU - Wardak, Zabi

AU - Choe, Kevin S.

PY - 2013

Y1 - 2013

N2 - Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poor. Utilizing powerful large-scale molecular techniques, several key pathways implicated in gliomagenesis have recently been identified and confirmed. These represent potential therapeutic targets, and by developing novel methods to specifically manipulate these pathways, we may achieve a meaningful and substantial improvement in the way we treat GBM. Here, we present and discuss the current status of research into the molecular pathways and potential therapeutic targets in GBM.

AB - Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poor. Utilizing powerful large-scale molecular techniques, several key pathways implicated in gliomagenesis have recently been identified and confirmed. These represent potential therapeutic targets, and by developing novel methods to specifically manipulate these pathways, we may achieve a meaningful and substantial improvement in the way we treat GBM. Here, we present and discuss the current status of research into the molecular pathways and potential therapeutic targets in GBM.

KW - GBM

KW - glioblastoma

KW - glioma

KW - glioma stem cells

KW - molecular target

KW - radiation

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84887298647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887298647&partnerID=8YFLogxK

U2 - 10.1586/14737140.2013.852472

DO - 10.1586/14737140.2013.852472

M3 - Article

C2 - 24168050

AN - SCOPUS:84887298647

VL - 13

SP - 1307

EP - 1318

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -